Cullinan Therapeutics (CGEM) Depreciation & Amortization (CF) (2020 - 2026)

Cullinan Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $79000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 3.95% year-over-year to $79000.0 in Q1 2026; TTM through Mar 2026 was $314000.0, a 2.61% increase from a year earlier, with the FY2025 full-year figure at $311000.0, up 1.63% from the prior year.
• Depreciation & Amortization (CF) was little changed at $79000.0 in Q1 2026 per CGEM's latest filing, from $79000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $81000.0 in Q2 2023 and bottomed at $9000.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $77000.0 (2023), against an average of $64647.1.
• Across the five-year window, Depreciation & Amortization (CF) slumped 30.77% in 2022 and soared 788.89% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $59000.0 in 2022, then soared by 30.51% to $77000.0 in 2023, then changed by 0.0% to $77000.0 in 2024, then gained by 2.6% to $79000.0 in 2025, then changed by 0.0% to $79000.0 in 2026.
• Per Business Quant, the three latest CGEM Depreciation & Amortization (CF) figures stand at $79000.0 (Q1 2026), $79000.0 (Q4 2025), and $79000.0 (Q3 2025).